Quince Therapeutics sells Italian unit and A-T drug technology to Ayma for $450,000

Quince Therapeutics, Inc. completed a divestiture on September 8, 2026, transferring its Quince Therapeutics SpA subsidiary along with related intellectual property and equipment to Ayma Therapeutics, Inc., according to an 8-K filed with the SEC. The deal covered all equity interests in Quince Therapeutics SpA, intellectual property tied to the company's Autologous Intracellular Drug Encapsulation technology for treating Ataxia-Telangiectasia through its eDSP product candidate (dexamethasone sodium phosphate encapsulated in patient's own red blood cells), and the associated AIDE and eDSP machines and systems.¹ In return, Ayma provided $450,000 in cash to Quince as consideration for the equity interests, intellectual property assets, and systems.¹

The physical assets involved were substantial: the purchased assets included roughly 20 AIDE and eDSP units located at Italian facilities and about 35 units at various clinical trial sites, along with consumables and kits.¹

Quince's pro forma disclosures show the transaction's financial effects. The company estimated a preliminary gain on the sale of the subsidiary tied to derecognizing the assets sold and liabilities transferred, factoring in the $0.5 million in closing proceeds and elimination of accumulated other comprehensive income linked to the Italian subsidiary.¹ Management said it would finalize this computation during the third quarter of 2026, cautioning that the actual gain could differ significantly from the estimate.¹

Separately, the filing disclosed a leadership change. Charles Ryan, the company's president, had his last day of employment on September 8, 2026, the same date as the closing.¹ Under his separation agreement, Ryan is set to receive a lump-sum payment of $1,014,489.04, covering 18 months of base salary, 150% of his prorated 2026 target bonus, and 18 months of COBRA premium coverage.¹